- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03223974
Clinical Trial on Safety and Efficacy of Drug-coated Balloon in Treatment of Coronary Bifurcation Lesions (BJDCB-BIF)
March 21, 2022 updated by: Xue Yu, Beijing Hospital
The objective of this study is to evaluate the safety and efficacy of paclitaxel-coated balloon in treatment of coronary bifurcation lesions.
This is a feasible study to demonstrate the noninferiority of paclitaxel Drug-coated balloon(DCB) only strategy for bifurcation lesions when compared with traditional single drug eluting stent(DES) strategy, so as to simplify the procedure for treatment of coronary bifurcation lesions and extending the clinical indications of paclitaxel DCB in China.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Paclitaxel DCB is designed to release anti-proliferative agents to the whole lesion rapidly and homogenously to inhibit excessive neointima proliferation and is associated with rapid healing of endothelium.
As a result, DCB therapy reduces the risk of coronary thrombosis.
Since only 1 to 3 months duration of dual anti-platelet therapy is required, the bleeding risk associated with prolonged dual anti-platelet therapy (DAPT) is reduced by DCB.
Furthermore, there is no permanent residue of foreign bodies in the blood vessels after DCB procedure and this advantage completely eliminates adverse events associated with allergic reactions to metal, polymer and stent fracture.
For side branch(SB) with a relatively small lumen in bifurcation lesions, DCB may neglect the lumen loss due to stent scaffolds and cause much less late lumen loss (LLL) than stent therapy does.
For main branch(MB), no jailed SBs by the stent and the rate of SB stenosis or even occlusion will be greatly reduced.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Beijing Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
Patient-related criteria:
- Patients with stable angina, unstable angina, old myocardial infarction or evidence of asymptomatic myocardial ischemia and consent to receive coronary intervention therapy;
- Aged between 18 and 80 years;
- Consent to receive angiographic follow up at 9 months and clinical follow up at 30 days, 6, 9, 12 and 24 months.
Lesion-related criteria:
- Target lesions of Medina (0,1,1), (1,0,1) or (1,1,1) primary coronary bifurcation lesions without previous intervention therapy;
- MB reference vessel diameter between 2.5 mm and 3.5 mm and length ≤30mm; SB reference vessel diameter between 2.0 mm and 3.0 mm and length ≤22 mm;
- Pre-operative vessel diameter stenosis must ≥70% or ≥50% associated with local ischemia;
- After lesion predilation, no dissection is seen, or type A/B dissection can be seen, residual stenosis ≤30% and TIMI(thrombolysis in myocardial infarction) grade 3 flow;
- The distance between other lesions requiring intervention therapy and the target lesion must >10mm ;
- Only one drug-eluting balloon or drug-eluting stent is used in treatment of MB and SB lesions.
Exclusion Criteria:
Patient-related criteria:
- Myocardial infarction in the previous week;
- Severe congestive heart failure[LVEF <30% or NYHA( New York Heart Association) III/IV)]
- Severe valvular heart disease;
- Pregnant or breastfeeding women;
- Life expectancy no more than 1 year or factors causing difficulties in clinical follow up;
- Bleeding predisposition, contraindications of anticoagulants or antiplatelet agents;
- Intolerance to aspirin and/or clopidogrel;
- Known intolerance or allergy to heparin, contrast agents, paclitaxel, iopromide, rapamycin, polylactic acid-glycolic acid copolymer, Co-Cr alloy or platinum-chromium alloy;
- Leukopenia or thrombopenia;
- A history of peptic ulcer or GI bleeding in the previously;
- Stroke within 6 months prior to the operation;
- A history of severe hepatic or renal failure.
Lesion-related criteria :
- Extensive thrombosis in the target vessel;
- Percutaneous coronary intervention of the graft vessel;
- Chronic total occlusions (pre-operative TIMI grade 0 flow);
- Left main branch lesions and /or three-vessel lesions requiring treatment;
- Lesions that are not indications of PTCA(percutaneous transluminal coronary angiography) or other intervention therapy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paclitaxel DCB for MB and/or SB
Balloon/vessel diameter ratio 0.8-1.0,
8-10 ATM(atmosphere), lasting for >30 seconds
|
Balloon/vessel diameter ratio 0.8-1.0,
8-10 ATM, lasting for >30 seconds.
If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
|
Active Comparator: DES in MB
with regular techniques
|
MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
QCA(quantitative coronary analysis) of efficacy of DCB
Time Frame: Follow-up coronary angiography at 9 months after the procedure
|
late lumen loss, minimal lumen diameter
|
Follow-up coronary angiography at 9 months after the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
device-related ischemic events
Time Frame: Clinical follow up at 30 days, 6, 9, 12 and 24 months after the procedure
|
including cardiovascular death, target vessel related myocardial infarction and ischemia-driven revascularization
|
Clinical follow up at 30 days, 6, 9, 12 and 24 months after the procedure
|
patient-related ischemic events
Time Frame: Clinical follow up at 30 days, 6, 9, 12 and 24 months after the operation
|
all myocardial infarction , any revascularization and all-cause death
|
Clinical follow up at 30 days, 6, 9, 12 and 24 months after the operation
|
ARC(Academic Research Consortium) defined target vessel thrombus events
Time Frame: Clinical follow up at 30 days, 6, 9, 12 and 24 months after the operation
|
definite, probable and possible target vessel thrombus
|
Clinical follow up at 30 days, 6, 9, 12 and 24 months after the operation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 16, 2017
Primary Completion (Actual)
November 30, 2019
Study Completion (Actual)
February 28, 2021
Study Registration Dates
First Submitted
July 15, 2017
First Submitted That Met QC Criteria
July 17, 2017
First Posted (Actual)
July 21, 2017
Study Record Updates
Last Update Posted (Actual)
March 22, 2022
Last Update Submitted That Met QC Criteria
March 21, 2022
Last Verified
March 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BJYY121-2016003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Disease
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking University Third HospitalCompletedCoronary Microvascular Dysfunction | Obstructive Coronary Heart DiseaseChina
-
Centro de estudios en Cardiologia IntervencionistaCompletedCoronary Heart Disease | Coronary RestenosisArgentina
-
Seung-Jung ParkCardioVascular Research Foundation, KoreaRecruitingCoronary Stenosis | Coronary Artery Bypass Grafting | Coronary Artery Disease Progression | Percutaneous Coronary RevascularizationKorea, Republic of
-
Deutsches Herzzentrum MuenchenCompletedCoronary Heart DiseaseGermany
-
Istanbul UniversityCompletedIschemic Heart Disease | Coronary Microvascular Disease | Microvascular Angina | Coronary Microvascular Dysfunction | Non-Obstructive Coronary Atherosclerosis | Microvascular Coronary Artery DiseaseTurkey
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
National Heart Centre SingaporeUnknownCoronary Heart DiseaseSingapore
Clinical Trials on Paclitaxel DCB
-
Rabih A. ChaerCompleted
-
University Hospital, EssenRecruitingPeripheral Arterial Disease | Drug Eluting Balloon | Infrainguinal Peripheral Arterial Disease | Flow-mediated DilationGermany
-
Beijing HospitalRecruiting
-
Yonsei UniversityRecruitingFemoropopliteal Artery DiseaseKorea, Republic of
-
Xiamen Cardiovascular Hospital, Xiamen UniversityRecruiting
-
Peking University Third HospitalNot yet recruitingCoronary Artery DiseaseChina
-
Acotec Scientific Co., LtdShanghai Tongji Hospital, Tongji University School of MedicineRecruiting
-
C. R. BardCompletedFemoral Artery Occlusion | Femoral Artery Stenosis | Stenosis of Popliteal Arteries | Occlusion of Popliteal ArteriesChina
-
Urotronic Inc.Active, not recruitingBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyDominican Republic, Panama
-
ReFlow Medical, Inc.Massachusetts General Hospital; Syntropic CorelabCompletedCritical Limb IschemiaDominican Republic